TNF inhibitors offered greater protection against fractures than NSAIDs in patients with axial spondyloarthritis (axSpA).
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...
AxSpA can bring on plantar fasciitis, which is when inflammation in the heel causes the sole of your foot to hurt. You may ...
Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
MRT-6160 is under development for the treatment of axial spondyloarthritis, rheumatoid arthritis, multiple sclerosis, Myasthenia Gravis, psoriasis, cutaneous lupus erythematosus a ...
Companies like Janssen, Pfizer, UCB, Amgen, and AbbVie are advancing axial spondyloarthritis treatments, focusing on improving symptoms and patient outcomes. LAS ...
Upadacitinib vs placebo demonstrated lasting efficacy and safety over 52-weeks of treatment among patients with nr-axSpA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback